Importance Evidence to support initiation of pharmacologic treatment in low-risk patients
with mild hypertension is inconclusive, with previous trials underpowered to demonstrate …

Background People with no previous cardiovascular events or cardiovascular disease
represent a primary prevention population. The benefits and harms of treating mild …

The benefit gained from antihypertensive treatment can vary widely across different groups
of patients. For example, in one randomized trial approximately eight fatal or non-fatal …

initiation of pharmacotherapy at a threshold of 140/90 mm Hg even in low-risk patients with
high BP, 1 whereas Hypertension Canada recommends treatment at 160/100 mm Hg3 …

James Wright and colleagues re-ported results of a meta-analysis of data on the effects of
various antihypertensive drugs. 1 Their stated purpose was to assist physicians in choosing …

Background Although hypertension guidelines define treatment-resistant hypertension as
blood pressure uncontrolled by≥ 3 antihypertensive medications, including a diuretic, it is …

Context Cardiovascular disease (CVD) risk increases beginning at systolic blood pressure
levels of 115 mm Hg. Use of antihypertensive medications among patients with a history of …

Hypertension is one of the most important risk factors for cardiovascular and renal diseases.
Currently, approximately 73 million adults in the United States and approximately 1 billion …

Background: The lower rate of primary outcome events in the intensive treatment group in
SPRINT (Systolic Pressure Intervention Trial) was associated with increased clinically …

Objective: To evaluate whether drug treatment for mild-to-moderate hypertension in middle-
aged patients improves survival and to study how the conflicting results of individual trials …